Scribe Therapeutics closes IPO of 9,867,000 shares at $15.00 each, including full over-allotment option
AI Market Summary
Scribe Therapeutics (Nasdaq: SCTX) closed an upsized IPO and a concurrent private placement to Sanofi, raising about $155.5M gross. This is a company-specific biotech financing event that can support SCTX's clinical programs but has limited read-through for broader equity indices, macro assets, or crypto. Any near-term market effect is likely confined to stock-level flows and biotech risk appetite rather than cross-asset repricing.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-0.34%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Scribe Therapeutics (Nasdaq: SCTX) said it closed its initial public offering on July 24, 2026, selling 9,867,000 shares at $15.00 per share, including the full exercise of the underwriters’ over-allotment option. The company said aggregate gross proceeds, including a concurrent private placement, were approximately $155.51 million before underwriting discounts and commissions. It also said it sold 500,000 shares to Sanofi in a concurrent private placement at the IPO price. Scribe describes itself as a clinical-stage biotechnology company developing in vivo CRISPR-based genetic medicines, with lead candidate STX-1150 designed to epigenetically silence PCSK9.
